{
  "doi": "10.1016/j.ijcard.2014.09.011",
  "full_text": "InternationalJournalofCardiology177(2014)171\u2013177\nContentslistsavailableatScienceDirect\nInternational Journal of Cardiology\njournal homepage: www.elsevier.com/locate/ijcard\nRenal function largely influences Galectin-3 prognostic value in\n\u2606\nheart failure\nElisabetZamoraa,b,1,JosepLup\u00f3na,b,1,MartadeAntonioa,b,1,AmparoGal\u00e1nc,1,MarDomingoa,1,\nAgust\u00ednUrrutiaa,b,1,MaribelTroyaa,b,1,AntoniBayes-Genisa,b,\u204e,1\naHeartFailureUnit,HospitalUniversitariGermansTriasiPujol,Badalona,Spain\nbDepartmentofMedicine,AutonomousUniversityofBarcelona,Spain\ncBiochemistryService,HospitalUniversitariGermansTriasiPujol,Badalona,Spain\na r t i c l e i n f o a b s t r a c t\nArticlehistory: Background:Galectin-3(Gal-3)hasbeenassociatedwithcardiacremodelingandheartfailure(HF)prognosis.\nReceived2June2014 RenalfunctionisalsoawellknownHFprognosticindicator.Thelinkbetweenrenalinsufficiency,HF,andGal-\nReceivedinrevisedform8August2014 3isnotcompletelyelucidated.\nAccepted15September2014 Methodsandresults:WeexploredtheassociationbetweenGal-3andrenalfunctioninacohortof876consecutive\nAvailableonlinexxxx\nambulatorypatientswithHF(meanage:68years;meanleftventricularejectionfraction[LVEF]:36%),52.2%had\nHFetiologyofischemicheartdisease.CirculatingGal-3washighlycorrelatedwithestimatedglomerularfiltra-\nKeywords:\ntion rate (eGFR), calculated with either the chronic kidney disease-epidemiology (CKD-EPI) equation\nHeartfailure\n(r=\u22120.64)ortheCKD-EPI-cystatin-Cequation(r=\u22120.59)andwithCystatin-Clevels(r=0.70),after\nRenalfailure\nMyocardialfibrosis adjusting for age, sex, New York Heart Association (NYHA) functional class, LVEF, and HF etiology (all\nRemodeling pb0.001).PatientswerestratifiedbyCKD-EPI-eGFR(ml/min/1.73m2),asfollows:\u226560(n=218),30to59\nBiomarkers (n=434),andb30(n=224).Inthesestrata,Gal-3significantlyincreased(median[IQR]:12.3[10.4\u201315.6];\n16.1[13\u201319.8];and24.5[20\u201333.8]ng/ml,respectively;trendpb0.001).ThiswasindependentofNYHAfunc-\ntionalclass(I\u2013IIandIII\u2013IV)andLVEF(b45%and\u226545%).Gal-3wasassociatedwithmortalityinunivariateanal-\nyses,butafteradjustingforCKD-EPI-eGFR,thehazardratioswere1.10(95%CI:0.89\u20131.34,p=0.39)forallcause\ndeath,and0.90(95%CI:0.68\u20131.21,p=0.50)forcardiovasculardeath.SimilarresultswereobtainedwitheGFRs\ncalculatedwiththeCKD-EPI-cystatin-Cequation.\nConclusion:CirculatingGal-3washighlyassociatedwithrenalfunctioninoutpatientswithHF.ThevalueofGal-3\nforHFprognosisdeclinedafteradjustingforrenalfunction.\n\u00a92014ElsevierIrelandLtd.Allrightsreserved.\n1.Introduction systemicchangesinHFpromotetheexpressionofinflammatoryand\nprofibroticmediatorsinvolvedinmanypathophysiologicalpathways.\nRiskstratificationiscrucialforpatientswithheartfailure(HF).Be- Galectin-3(Gal-3)isasoluble\u03b2-galactosidase-bindingglycoprotein\nyondclinicalfactors,severalcirculatingbiomarkershavebeendescribed releasedbyactivatedmacrophages.Gal-3regulatesfibrogenesis,in-\nassignificantly useful in riskstratification [1,2].Complex localand flammation,tissuerepair,andcellproliferation[3].Gal-3stimulates\nmyofibroblastproliferationandprocollagen-1deposition,whicheven-\ntuallycontributestomyocardialremodeling[4].Severalstudieshave\nsuggestedthatelevatedGal-3levelswereassociatedwithapoorprog-\nAbbreviations:CKD-EPI,chronickidneydisease-epidemiologyequation;CI,confidence\ninterval;eGFR,estimatedglomerularfiltrationrate;Gal-3,Galectin-3;HF,heartfailure;HR,\nnosisinpatientswithHF[5\u20137],butrecentreportswithmultivariable\nhazardratio;IQR,interquartilerange;LVEF,leftventricularejectionfraction;NYHA,New adjustmentshavecastdoubtonthatassociation[8\u201311].\nYorkHeartAssociationfunctionalclass. RenalfunctionisarecognizeddeterminantofHFoutcomesandmay\n\u2606 Fundinginformation:Galectin-3assayswerepartiallyprovidedbyBiomerieux. influencecirculatinglevelsofdifferentbiomarkers.Previousstudies\nCystatin-CassayswereprovidedbyRadimIb\u00e9rica(Barcelona,Spain).Neitherofthese\nsuggestedthatcirculatingGal-3levelsmayincreaseinpatientswith\ncompanieshadanyroleinthedesignofthestudynorthecollection,management,analy-\nsis,norinterpretationofthedata.\npoorrenalfunction,butthisrelationshipwasinsufficientlyexamined,\n\u204e Correspondingauthorat:HeartFailureUnit.DepartmentofMedicine,UAB,Hospital andtheeffectsofrenalfunctiononGal-3werenotcompletelyelucidat-\nUniversitariGermansTriasiPujol,CarreteradelCanyets/n08916,Badalona,Spain. ed[5,7].Evenlessisknownaboutwhetherrenalfunctioninfluencesthe\nTel.:+34934978915;fax:+34934978939. abilityofGal-3topredictoutcomesinpatientswithHF[5\u20137,9,12].Ac-\nE-mailaddress:abayesgenis@gmail.com(A.Bayes-Genis).\n1 Thisauthortakesresponsibilityforallaspectsofthereliabilityandfreedomfrombias cordingly,ourobjectivewastoassesstheassociationbetweenGal-3\nofthedatapresentedandtheirdiscussedinterpretation. andrenalfunctionandtoanalyzetheinfluenceofrenalfunctionon\nhttp://dx.doi.org/10.1016/j.ijcard.2014.09.011\n0167-5273/\u00a92014ElsevierIrelandLtd.Allrightsreserved.\n172 E.Zamoraetal./InternationalJournalofCardiology177(2014)171\u2013177\ntheprognosticvalueofGal-3inalargeconsecutive,cohortofambulato- AllanalyseswereperformedwithSPSS15(SPSSInc.,Chicago,IL).Atwo-sidedpb0.05\nrypatientswithHF.\nwasconsideredsignificant.\n2.Methods 3.Results\n2.1.Studypopulation\nOutof891consecutivepatientsincludedfromMay22,2006toJuly\nThepresentstudywasapost-hocanalysisofapatientseriesreportedelsewhere[13].\n7,2010,876hadGal-3andeGFRdata;thus,876patientswerefinallyin-\nFromMay22,2006toJuly7,2010,ambulatorypatientstreatedatamultidisciplinaryHF cludedinthissubanalysis(meanage68\u00b112.4years).Themainetiol-\nunitwereconsecutivelyincludedinthestudy.Referrals,inclusioncriteria,andbloodsam- ogyofHFwasischemicheartdisease(52.2%)andthemeanLVEFwas\nplecollectionprocedureshavebeendescribedelsewhere[14,15].Aftercollection,blood 36\u00b114%.MostpatientswereclassifiedasNYHAclassII(65.8%)orIII\nsampleswerecentrifuged,andserumsampleswerestoredat\u221280\u00b0C.Allbiomarkers,in-\n(25.9%).Table1showsthebaselinecharacteristicsofthesample.During\ncludingcreatinine,wereanalyzedinthesamebloodsample.\nAllparticipantsprovidedwritteninformedconsent,andthelocalethicscommittee ameanfollow-upof4.2\u00b12.1years,392patientsdied(44.7%),221\napprovedthestudy.Allstudyprocedureswereinaccordancewiththeethicalstandards (25.2%)fromCVcauses.MortalityratesindifferentCKD-EPI-eGFRstrata\noutlinedintheHelsinkiDeclarationof1975,asrevisedin1983. were22.9%(50/218patients)foreGFR\u226560ml/min/1.73m2;45.6%\n(198/434patients)foreGFR30 to b60ml/min/1.73m2;and64.3%\n2.2.Follow-upandoutcomes\n(144/224patients)foreGFRb30ml/min/1.73m2.Fivepatientswere\nAllpatientswerefollowedatregular,predefinedintervals,withadditionalvisitsasre- losttofollow-up,andtheywereadequatelycensored.\nquired,incaseofdecompensation[14,15].Follow-upwasclosedonthe31stofMarch\n2013.Deathfromallcauseswasthemainoutcome.Cardiovascular(CV)deathwasalso\n3.1.Gal-3correlationswithrenalfunctionsurrogates\nassessedandassecondaryend-pointthecompositeoutcomeofCVdeathandHFhospital-\nizationwasalsoanalyzed.AdeathwasconsideredCVinoriginwhenitwascausedby:HF\n(decompensatedHFortreatment-resistantHF);suddendeath;acutemyocardialinfarc- Gal-3concentrationshighlyinverselycorrelatedwithCKD-EPI-eGFR\ntion;stroke;CVprocedural;andotherCVcauses.Weidentifiedfataleventsinclinicalre- (Rho\u22120.60,pb0.001,Fig.1).Thiscorrelationfurtherincreasedafter\ncordsfromtheHFunit,otherhospitalwards,theemergencyroom,generalpractitioners,\nadjustingforage,sex,NYHAfunctionalclass,LVEF,andHFetiology(is-\nandbycontactingthepatient'srelatives.Furthermore,recordswereverifiedbychecking\ndatabasesmaintainedbytheCatalanandSpanishHealthSystems.\nchemicvs.non-ischemic)(r=\u22120.64,pb0.001).RelativetotheeGFR\nstrata,circulatingGal-3significantlyincreasedwithworseningeGFR.\n2.3.Serumcreatinineassay Themedian(IQR)Gal-3concentrationswere12.3(10.4\u201315.6)ng/ml\nforeGFR\u226560ml/min/1.73m2;16.1(13\u201319.8)ng/mlforeGFR30to\nSerumcreatinineconcentrationwasanalyzedwiththeSiemensCREAmethod(ref b60ml/min/1.73m2;and24.5(20\u201333.8)ng/mlforeGFRb30ml/min/\nFD33A)onaDimension\u00aeRxLClinicalChemistrySystem(Siemens,Newark,USA).Creati-\nninevalueswerestandardizedaccordingtotheisotopedilutionmassspectrometry\n1.73m2(pfortrendb0.001,Fig.2).Thisrelationshipwasindependent\n(IDMS)method,asrecommendedbythemanufacturer(TechnicalBulletin:Correlation\nfactorsforcorrelatingJaffecreatininemethodstotheIDMScreatininereferenceproce- Table1\ndure,D-01674SiemensHeallthcareDiagnostics,Inc.,March2011,rev1.0).Thestandard- Demographicandclinicalbaselinecharacteristicsandtreatmentsofpatientswithheart\nized creatinine values were calculated as follows: standardized creatinine values failure.a\u2013f\n(mg/dl)=1.00\u00d7Dimension\u00aeRxLcreatininevalues(mg/dl)\u2212[0.168].\nVariables PatientsN=876\n2.4.Estimatedglomerularfiltrationrate\nAge,yearsc 68\u00b112.4\nEstimatedglomerularfiltrationrate(eGFR)wascalculatedwiththechronickidney Females 249(28.4)\nEtiology\ndisease-epidemiology(CKD-EPI)equation[16].Asacomplementaryanalysis,theCKD-\nIschemicheartdisease 457(52.2)\nEPI-Cystatin-Cequation[17]wasalsoused.\nDilatedcardiomyopathy 85(9.7)\nHypertensive 81(9.2)\n2.5.Gal-3assay\nValvedisorder 103(11.8)\nAnenzyme-linkedfluorescentassay(BioMerieuxref.411191)onamini-VIDAS\u00aean- Other 150(17.1)\nalyzer(BioMerieux,France)wasused.Thecoefficientofvariationfortheassaywasb10%, LVEF,%c 36\u00b114\nthelinearrangewas3.3\u2013100.0ng/ml,andthelimitofdetectionwas2.4ng/ml. eG eF GR F, Rm \u2265l/m 6i 0n/1.73m2c,d 4 26 1. 82 (\u00b1 242 .92 ).3\nForcorrelationanalysesbetweenGal-3andCystatin-C,standardizedserumconcen- eGFR\u226530andb60 434(49.5)\ntrationsofthelatterwereusedandmeasuredaspreviouslydescribed[18]. eGFRb30 224(25.6)\nNYHAfunctionalclass\n2.6.Statisticalanalysis\nI 64(7.3)\nII 576(65.8)\nCategorical variables are expressed as percentages. Continuous variables are\nIII 227(25.9)\nexpressedasmean\u00b1SD,andmedian(interquartilerange[IQR]),forcaseswithskewed\nIV 9(1.0)\ndistributions.NormaldistributionwasassessedwithnormalQ\u2013Qplots.TheSpearman\nHypertension 534(61.0)\ntestwasusedtoanalyzecorrelationsbetweeneGFRandGal-3.TheLoess-basedapproach\nDiabetesmellitus 315(36.0)\nwasusedtoobtaintotaladjustmentcurves.Unadjustedandadjustedcorrelationanalyses\nTreatments(follow-up)\nbetweenGal-3andCystatin-Cwereperformedafterlogarithmictransformation.Patients\nACEIorARB 786(89.7)\nwerestratifiedbyeGFRasfollows(inml/min/1.73m2):b30;30tob60and\u226560.Statisti-\nBeta-blocker 767(87.6)\ncaldifferences(p-valuefortrend)inGal-3concentrationsbetweengroupswereanalyzed\nMRA 342(39.0)\nwiththeSpearmantest.\nLoopdiuretic 742(84.7)\nSurvivalanalyseswereperformedwithCoxregressionmodels.Tofulfilltheassump-\nDigoxin 265(30.3)\ntionthattheco-variableGal-3waslinear,itslogarithmicfunctionwasused,anda1SD Galectin-3,ng/mle 16.5(12.6\u201322.7)\nincreasewasusedforhazardratio(HR)calculations(NT-proBNPwassimilarlytrans- CystatinC,mg/le,f 1.33(1.07\u20131.79)\nformed).UnivariateCoxregressionanalyseswereperformedandadjustedforeGFRand\nfortheco-variableinteractioneGFR*Gal-3(log-transformed)whenall-causeandCV a LVEF=leftventricularejectionfraction;eGFR=estimatedglomerularfiltration\ndeathwereanalyzed,owingtothesignificantinteractionbetweenbothindependentvar- rate;NYHA=NewYorkHeartAssociation;ACEI=angiotensin-convertingenzymein-\niables,whichmeansthattheprognosticimplicationofGal-3isnotthesameatalllevelsof hibitor;ARB=angiotensinIIreceptorblocker;andMRA=mineralcorticoidreceptor\neGFR.Also,multivariateCoxregressionsurvivalanalyseswereperformedforall-cause antagonist.\ndeathandCVmortalityincludingage,sex,NewYorkHeartAssociation(NYHA)functional b Dataareexpressedasthenumberofpatients(percentage),unlessotherwise\nclass,leftventricularejectionfraction(LVEF),ischemicetiologyofHF,treatments,eGFR, indicated.\nandtheinteractioneGFR*Gal-3.Thisco-variablewasnotincludedintheanalysisofthe c Mean\u00b1SD.\ncompositeend-pointCVdeathorHFhospitalizationduetotheabsenceofinteractionin d eGFRcalculatedwithCKD-EPIequation.\nthisparticularitem.Finally,Coxregressionsurvivalcurveswereplottedforthedifferent e MedianIQR.\neGFRstrata,basedontheGal-3concentrationabove/belowthemedian. f Cystatindatawasavailablein865patients.\nE.Zamoraetal./InternationalJournalofCardiology177(2014)171\u2013177 173\nobtainedwhentheanalysisincludedeGFRcalculatedwiththeCKD-EPI-\ncystatin-Cequation(Table3).\nFocusingonrenalfunction,weperformedanadjustedCoxregression\nanalysisamongpatientswithoutrenalinsufficiency(eGFR\u226560ml/min/\n1.73m2).WhenGal-3wasusedasacontinuousvariable,itwasnotasso-\nciatedwitheitherall-causedeath(HR1.01,95%CI:0.69\u20131.47;p=0.97)\norCVdeath(HR1.13,95%CI:0.67\u20131.89;p=0.65).WhenGal-3wasdi-\nchotomized into values above/below the median, the associations\nremainedinsignificant(all-causedeath,Fig.5A).Similarly,whenpatients\nwithsevererenalinsufficiency(eGFRb30ml/min/1.73m2)wereana-\nlyzedwiththeadjustedCoxregression,Gal-3(continuousvariable)did\nnotshowsignificantassociationsforallcausedeath(HR1.09,95%CI:\n0.90\u20131.3,p=0.40)orforCVdeath(HR1.05,95%CI:0.82\u20131.35;p=\n0.70).TheassociationsremainedinsignificantwhenGal-3wasdichoto-\nmizedintovaluesabove/belowthemedian(all-causedeath,Fig.5B).\nIn contrast, in patients with intermediate renal insufficiency\n(eGFR\u226530tob60ml/min/1.73m2),Gal-3waspredictiveasacontinu-\nousvariableforallcausedeath(HR1.53,95%CI:1.27\u20131.84;pb0.001)\nandforCVdeath(HR1.50,95%CI:1.17\u20131.92;p=0.001).Theseassoci-\nFig.1.ScatterplotofGal-3serumconcentrationsandeGFRvalues.Gal-3serumconcentra- ationsremainedsignificantwhenGal-3wasdichotomizedtovalues\ntionssignificantlyincreasedwithloweGFR.BlackcurvedlineshowsthefitwiththeLoess\nabove/belowthemedian(all-causedeath,Fig.5C).However,evenin\nadjustment.\nthesepatients,wheneGFRandtheinteractioneGFR*Gal-3covariate\nofNYHAfunctionalclass(I\u2013IIandIII\u2013IV)andLVEF(b45%and\u226545%)\nwereincludedintheanalyses,Gal-3lostitssignificanceasanindepen-\n(allpb0.001,Fig.3). dentriskfactorformortality,whetheritwasusedasacontinuousvar-\niable(HR1.68,95%CI:0.59\u20134.76;p=0.33forallcausedeath,andHR\nCystatin-Cdatawasavailablein865patients.Gal-3andCystatin-C\nconcentrationssignificantlycorrelated(r=0.73,pb0.001,Fig.4),\n0.64,95%CI:0.15\u20132.75;p=0.56forCVdeath)orasacategoricalvari-\nable(HR1.31,95%CI:0.88\u20131.95;p=0.182forallcausedeath).\nevenafteradjustmentsforage,sex,NYHAfunctionalclass,LVEF,and\nHFetiology(ischemicvs.non-ischemic)(r=0.70,pb0.001).\nOntheotherhand,Gal-3wassignificantlyassociatedwiththecom-\npositeend-pointCVdeathorHFhospitalizationintheunivariateanaly-\nNext,eGFRwascalculatedwiththeCKD-EPI-cystatin-Cequation.\nsis.Aftertheadjustmentbyrenalfunctionitremainedsignificantorof\nThecorrelationbetweenGal-3andeGFRremainedhigh,bothbefore\n(Rho = \u22120.70, p b0.001) and after adjusting for the covariates\nborder-linesignificance,dependingontheeGFRequationused:CKD-\n(r=\u22120.59,pb0.001).\nEPI(HR1.21[1.06\u20131.36],p=0.005);CKD-EPI-CystatinCequation\n(HR1.15[1.00\u20131.33],p=0.051).However,Gal-3lostitssignificant\nassociationwiththecompositeend-pointinthemultivariateanalysis,\n3.2.Outcomes,renalfunction,andGal-3\neitherwhetherrenalfunctionwasincludedornot(Supplementaryon-\nlineTable1).\nInaunivariateanalysis,Gal-3wasassociatedwithall-causeandCV\ndeaths(Table2).However,afteradjustingforeGFRandtheinteraction\n4.Discussion\ncovariate,eGFR*Gal-3,Gal-3lostitsindependentprognosticvaluefor\nbothall-causeandCVmortality.\nFibrosisisafundamentalcomponentofadversestructuralremodel-\nWeperformedamultivariateanalysisthatincludedage,sex,NYHA\ning,inboththemyocardiumandthekidney[19,20].Amultitudeofreg-\nfunctionalclass,LVEF,ischemicetiology,andtreatments.Inthisanaly-\nulatorsareinvolvedinthepathophysiologyoffibrosis,includingGal-3;\nsis, Gal-3 remained associated with all-cause death and CV death.\n[4]however,itremainsuncertainwhethercirculatingGal-3levelsre-\nHowever,whenrenalfunctionwasincludedinthemodel,Gal-3lostsig-\nflectfibrosislevelsinthemyocardium,kidney,orotherorgans.\nnificantassociationswithbothoutcomes(Table2).Similarresultswere\nStudiesinthehearthaveproducedcontroversialresults.DeBoeretal.\n[9]describedaweakcorrelationbetweenGal-3andpro-inflammatory\ncytokinesinacuteHF,butGopaletal.[21]didnotfindanyrelationship\nbetweenGal-3levelsandthepresenceorabsenceofHF,thelevelofde-\ncompensation,orthetypeofHF(preservedorreducedsystolicfunction).\nAlthoughHFwithpreservedLVEFwasassociatedwithinterstitialfibrosis\nanddiastolicdysfunction,Tangetal.[7]describedthelackofrelation-\nshipsbetweenGal-3andseveralechocardiographicmeasurementsof\ncardiacstructureandfunctioninchronicstableHF.Moreover,intheecho-\ncardiographicsubsetofthePRIDEstudy,Gal-3levelswereonlyslightly\nassociatedwithtwodifferentdiastolicparameters[22].Itisalsounclear\nwhetherGal-3ismodulatedbytreatment;nosignificantchangeswere\nobservedinGal-3bloodlevelsaftercardiacresynchronizationtherapy.\nThus,thecardiacfibrosismediatedbyGal-3maynotbeamajordetermi-\nnantofcardiacdyssynchrony[10].Furthermore,ithasbeenreportedthat\nserumGal-3levelsremainedelevated,despiteareplacementofthedis-\neasedmyocardiumandreversaloftheHFstatewithahearttransplant\n[23,24].Thosefindingssupportedthehypothesisthattissueandcirculat-\ningGal-3expressionweredissociated[7].\nInthekidney,therelationshipbetweenGal-3andeGFRisevenmore\nambiguous.Gal-3expressionpromotesrenalfibrosisinanimalmodels\nFig.2.BoxplotofGal-3serumconcentrationsaccordingtoeGFRstrata.P-valuesshow\ntrends.\u00b0=outliers,and*=extremevalues. [20],andGal-3mayplayaroleintubularatrophyandinterstitialfibrosis\n174 E.Zamoraetal./InternationalJournalofCardiology177(2014)171\u2013177\nFig.3.BoxplotofGal-3serumconcentrations,accordingtoeGFRstratainNYHAfunctionalclassandLVEFsubgroups.(a)NYHAclassesI\u2013II;(b)NYHAclassesIII\u2013IV;(c)LVEFb45%;\n(d)LVEF\u226545%.P-valuesshowtrends.\u00b0=outliers,and*=extremevalues.\nafterrenaltransplantationinmice[25].Gal-3seemedtoparticipatein Conversely,inanotherstudy,Gal-3showedaprotectiveeffectagainst\nrenal ischemic\u2013reperfusion injury that involved the secretion of ischemia/reperfusioninthekidney[27].Takentogether,thoseresults\nmacrophage-relatedchemokinesandpro-inflammatorycytokines[26]. suggestedthatGal-3mayplayadualrolethroughcomplexinteractions\ninthekidney.\nTherelationshipbetweenGal-3andkidneyfunctioninpatientswith\nHFhasbeenreportedpreviously,butwithoutin-depthinterpretations\n[3,5,8\u201310,12,21,22].Inourstudy,serumGal-3concentrationwashighly\ninversely-correlatedwitheGFR,evenafteradjustmentsforage,sex,\nNYHA functional class, LVEF, and HF etiology (ischemic vs. non-\nischemic)(r=\u22120.64,pb0.001).Whenpatientsweredividedinto\neGFRstrata,Gal-3levelssignificantlyincreasedaseGFRworsened,inde-\npendentoftheNYHAfunctionalclassandtheLVEF.Othershavefound\neven higher correlations between Gal-3 and eGFR (r = \u22120.82,\npb0.001)inpatientswithchronickidneydisease,but withoutHF\n[21].Thoseauthorsconcludedthatrenalimpairmentwasamajordeter-\nminantofplasmaGal-3expression,regardlessoftheexistence,type,\nandseverityofHF.Manypotentialmechanismsmayexplainthisphe-\nnomenon;forexample,Gal-3clearancemightbereducedinrenalinsuf-\nficiency[21]orGal-3productionmightbeenhancedbyafactoror\nfunctioninthekidney[21,26].\nMoreover,inthepresentstudy,Gal-3andCystatin-Cserumconcen-\ntrationsweresignificantlycorrelated,evenafteradjustingforage,sex,\nNYHA functional class, LVEF, and HF etiology (ischemic vs. non-\nischemic)(r=0.70,pb0.001).Thisassociationmightbeexplained\nFig.4.Gal-3andCystatin-Cserumconcentrationscorrelation.Bothbiomarkervalueswere\nbytheassociationofCystatin-Cwithalterationsintheextracellular\nlog-transformedforthecorrelationanalysis.Theblackcurvedlinerepresentsthetotallin-\nearadjustment. biomatrix [9]. Indeed, Cystatin-C is considered essentially a renal\nE.Zamoraetal./InternationalJournalofCardiology177(2014)171\u2013177 175\nTable2 Table3\nCoxregressionanalysesa,bforall-causeandcardiovascularmortality,withtheCKD-EPI Coxregressionanalysesa,bforall-causeandcardiovascularmortality,withtheCKD-EPI-\nequationfortheeGFRcalculation. Cystatin-CequationfortheeGFRcalculation.\nAll-causedeath Cardiovasculardeath All-causedeath Cardiovasculardeath\nHR 95%CI pvalue HR 95%CI pvalue HR 95%CI pvalue HR 95%CI pvalue\nUnivariateanalysis Univariateanalysis\nGalectin-3 1.54 [1.41;1.68] b0.001 1.59 [1.40;1.76] b0.001 Galectin-3 1.54 [1.41;1.68] b0.001 1.59 [1.40;1.76] b0.001\nAdjustedforrenalfunctiononly Adjustedbyrenalfunctiononly\nGalectin-3 1.00 [0.84;1.20] 0.99 0.87 [0.67;1.13] 0.30 Galectin-3 0.85 [0.71;1.02] 0.08 0.75 [0.57;0.97] 0.03\neGFR,ml/min/1.73m2 0.98 [0.98;0.99] b0.001 0.98 [0.97;0.99] b0.001 eGFR,ml/min/1.73m2 0.98 [0.97;0.98] b0.001 0.98 [0.97;0.98] b0.001\nInteraction 1.01 [1.00;1.01] b0.001 1.01 [1.01;1.02] b0.001 Interaction 1.01 [1.00;1.01] 0.001 1.01 [1.01;1.02] b0.001\neGFR*Galectin-3 eGFR*Galectin-3\nMultivariateanalysiswithoutrenalfunction Multivariateanalysiswithoutrenalfunction\nAge 1.04 [1.03;1.05] b0.001 1.03 [1.02;1.05] b0.001 Age 1.04 [1.03;1.05] b0.001 1.03 [1.02;1.05] b0.001\nSex 0.70 [0.55;0.89] 0.003 0.64 [0.47;0.89] 0.007 Sex 0.70 [0.55;0.89] 0.003 0.64 [0.47;0.89] 0.007\nLVEF 1.01 [1.00;1.02] 0.15 1.01 [1.00;1.02] 0.21 LVEF 1.01 [1.00;1.02] 0.15 1.01 [1.00;1.02] 0.21\nNYHAfunctionalclass 1.77 [1.47;2.13] b0.001 1.86 [1.46;2.37] b0.001 NYHAfunctionalclass 1.77 [1.47;2.13] b0.001 1.86 [1.46;2.37] b0.001\nIschemicetiology 1.10 [0.88;1.37] 0.39 1.25 [0.93;1.67] 0.14 Ischemicetiology 1.10 [0.88;1.37] 0.39 1.25 [0.93;1.67] 0.14\n\u03b2-blockertreatment 0.54 [0.41;0.71] b0.001 0.53 [0.37;0.77] 0.001 \u03b2-blockertreatment 0.54 [0.41;0.71] b0.001 0.53 [0.37;0.77] 0.001\nACEI\u2013ARBtreatment 0.81 [0.60;1.09] 0.16 0.74 [0.50;1.09] 0.12 ACEI\u2013ARBtreatment 0.81 [0.60;1.09] 0.16 0.74 [0.50;1.09] 0.12\nAMRtreatment 1.03 [0.84;1.27] 0.76 1.21 [0.92;1.59] 0.18 MRAtreatment 1.03 [0.84;1.27] 0.76 1.21 [0.92;1.59] 0.18\nNT-proBNP 1.45 [1.27\u20131.66] b0.001 1.49 [1.24\u20131.79] b0.001 NT-proBNP 1.45 [1.27\u20131.66] b0.001 1.49 [1.24\u20131.79] b0.001\nGalectin-3 1.19 [1.07;1.32] 0.001 1.21 [1.05;1.39] 0.009 Galectin-3 1.19 [1.07;1.32] 0.001 1.21 [1.05;1.39] 0.009\nMultivariateanalysiswithrenalfunction Multivariateanalysiswithrenalfunction\nAge 1.04 [1.03;1.05] b0.001 1.03 [1.01;1.04] 0.001 Age 1.03 [1.02;1.04] b0.001 1.02 [1.01;1.04] 0.01\nSex 0.70 [0.56;0.89] 0.003 0.65 [0.47;0.89] 0.008 Sex 0.68 [0.54;0.87] 0.002 0.63 [0.46;0.86] 0.006\nLVEF 1.01 [1.00;1.02] 0.15 1.01 [1.00;1.02] 0.20 LVEF 1.01 [1.00;1.01] 0.21 1.01 [1.00;1.02] 0.28\nNYHAfunctionalclass 1.77 [1.47;2.13] b0.001 1.86 [1.46;2.37] b0.001 NYHAfunctionalclass 1.71 [1.42;2.06] b0.001 1.75 [1.37;2.25] b0.001\nIschemicetiology 1.10 [0.88;1.37] 0.39 1.23 [0.92;1.66] 0.16 Ischemicetiology 1.10 [0.88;1.37] 0.42 1.23 [0.91;1.65] 0.18\n\u03b2-blockertreatment 0.53 [0.40;0.69] b0.001 0.52 [0.36;0.75] b0.001 \u03b2-blockertreatment 0.50 [0.38;0.66] b0.001 0.49 [0.34;0.71] b0.001\nACEI\u2013ARBtreatment 0.79 [0.59;1.07] 0.13 0.71 [0.48;1.05] 0.08 ACEI\u2013ARBtreatment 0.78 [0.58;1.06] 0.11 0.70 [0.47;1.04] 0.08\nMRAtreatment 1.01 [0.81;1.25] 0.96 1.13 [0.85;1.50] 0.40 MRAtreatment 0.99 [0.80;1.23] 0.90 1.11 [0.83;1.47] 0.48\nNT-proBNP 1.46 [1.27\u20131.67] b0.001 1.51 [1.26\u20131.82] b0.001 NT-proBNP 1.43 [1.24\u20131.65] b0.001 1.47 [1.22\u20131.79] b0.001\nGalectin-3 0.99 [0.80;1.22] 0.94 0.81 [0.61;1.09] 0.16 Galectin-3 0.83 [0.67;1.03] 0.09 0.69 [0.51;0.93] 0.01\neGFR,ml/min/1.73m2 1.00 [0.99;1.00] 0.22 0.99 [0.98;1.00] 0.07 eGFR,ml/min/1.73m2 0.99 [0.98\u20131.00] 0.01 0.99 [0.98\u20131.00] 0.009\nInteraction 1.01 [1.00;1.01] 0.08 1.01 [1.00;1.02] 0.004 Interaction 1.01 [1.00;1.01] 0.005 1.01 [1.01;1.02] 0.001\neGFR*Galectin-3 eGFR*Galectin-3\na HR=hazardsratio;eGFR=estimatedglomerularfiltrationrate;LVEF=leftven- a CKD-EPI-Cystatin-Cequation=equationthatincludeschronickidneydisease-\ntricularejectionfraction;NYHA=NewYorkHeartAssociation;ACEI=angiotensin- epidemiologyandcystatin-C;HR=hazardsratio;eGFR=estimatedglomerular\nconverting enzyme inhibitor; ARB=angiotensin II receptor blocker; and filtrationrate;LVEF=leftventricularejectionfraction;NYHA=NewYorkHeart\nMRA=mineralcorticoidreceptorantagonist. Association;ACEI=angiotensin-convertingenzymeinhibitor;ARB=angiotensin\nb ThelogarithmicfunctionofGalectin-3andNT-proBNPper1SDwasusedintheCox IIreceptorblocker;andMRA=mineralcorticoidreceptorantagonist.\nmodels. b ThelogarithmicfunctionofGalectin-3andNT-proBNPper1SDwasusedintheCox\nmodels.\nbiomarker;[28]itsprognosticvalueliesbothinitsabilitytoestimate eGFRvalue.ThiseffectontheGal-3HRwasmorepronouncedwhen\nrenalfunctionandinitsrelationshipswithventricularremodeling,fi- eGFRwascalculatedwiththeCKD-EPI-Cystatin-Cequation;thatequa-\nbrosis,andvascularwallstiffness[29].Ofnote,fromaprognosticper- tionwasshowntohavehigherprognosticvaluethanotherformulas\nspective,Cystatin-CandGal-3seemtohavebehavedquitesimilarlyin inHF[31].WhenweanalyzedthethreeeGFRstrata,weobservedthat\nourstudies[30].Bothwerehighlyinfluencedbyrenalfunction,and Gal-3wasnotassociatedwithall-causedeathorCVmortalityinthead-\nbothshowedprognosticsignificancethatvariedwiththeeGFR.Inapre- justedCoxregressionanalysisinpatientswithoutrenalinsufficiency\nviousreport,wefoundthatCystatin-Clevels[30]improvedriskstratifi- (eGFR\u226560ml/min/1.73m2).Incontrast,Gal-3hadhighpredictiveca-\ncation mainly in patients that had eGFR values of 30\u201360ml/min/ pacityforall-causedeathandCVdeathinpatientswithintermediate\n1.73m2,thesamepatientgroupthatshowedasignificantassociation renalinsufficiency(eGFR30tob60ml/min/1.73m2).However,Gal-3\nbetweenGal-3andmortalityinthepresentstudy. lostitspredictivecapacitywhenbotheGFRandtheinteractioneGFR*\nTheefficacyofGal-3asanindependentHFprognosticfactorishighly Gal-3covariatewereincludedintheanalysis.\ncontroversial.Thisuncertaintymayberelatedtorenalfunction.Inthe Basedonthedataabove,itisfarfromcertainwhetherGal-3should\npresentstudy,Gal-3wasonlyassociatedwithall-causedeathandCV beconsideredmoreacardiacorarenalmarker.Acombinationofboth\ndeathwhenrenalfunctionwasnotincludedinthepredictivemodel.In maybemostplausible,althoughwecannotdisregardthefactthatcircu-\notherstudies,liketheHF-ACTIONstudy[8]Gal-3lostprognosticsignifi- latingGal-3levelsandmyocardialtissueproductionofGal-3seemtobe\ncancewhenotherbiomarkers,suchasNT-proBNP,wereincludedinthe disconnectedinHF[9,23,24].Infact,Gal-3wasassociatedwithanin-\nmodel.Wedeliberatelyexcludedotherbiomarkersinourcurrentanalysis creasedriskofHFincidenceandmortalityinacommunity[32]and\n(i.e.,ST2,hs-TnT),becausepreviousreportsfromourgrouphaddemon- withanincreasedriskofrenalfailureincidenceinageneralpopulation\nstratedtheirsuperiorityoverGal-3[13].Instead,thepresentstudywas [33].Inthecontextofcardio-renalsyndrome,circulatingGal-3ap-\ndesignedtoexploretherelationshipbetweenGal-3andrenalfunction. pearedtoreflectinflammatory,profibroticstatesinbothcardiacand\nWeshowedthatthepredictivepowerofGal-3disappearedwhen renaltissues[22].Someimportantfactorsthatshouldbetakenintoac-\nrenalfunctionwasincludedintheanalyses.Asimilarphenomenon countarethewidespreadcellulardistributionofGal-3,itsinvolvement\nwas previously described for Cystatin-C [30]. Beyond that, unlike indifferentbiologicalprocesses,andthevariousfactorsthatmightaf-\notherstudies,weexaminedthepredictivepowerofGal-3atdifferent fectGal-3levels.Inaddition,ourknowledgeofGal-3pathophysiology\nstagesofrenalfunction.Remarkably,theGal-3HRforCVmortality remainslimited.Infact,thefibroticeffectsofGal-3mightbemediated\nchangedfromabove1tobelow1whenthemodelwasadjustedfor byorgansotherthantheheartandkidneyinthesettingofsystemicin-\neGFR. Thus, the prognostic significance of Gal-3 depended on the flammation,whenHFandrenalinsufficiencycoexist[21].\n176 E.Zamoraetal./InternationalJournalofCardiology177(2014)171\u2013177\nFig.5.SurvivalcurvesaccordingtoGal-3serumconcentrations.PatientsweregroupedaccordingtowhethercirculatingGal-3wasabove/belowthemedian.eGFRcalculatedwithCKD-EPI\nequation.(A)PatientswitheGFR\u226560ml/min/1.73m2(N=218).(B)PatientswitheGFRb30ml/min/1.73m2(N=224).(C)PatientswitheGFRbetween30and60ml/min/1.73m2\n(N=434).\nThisstudyhadsomelimitations.Becausewehadnoserialmeasure- collaborationwiththeInternationalSocietyforHeartandLungTransplantation.Circu-\nlation2009;119(14):1977\u20132016.\nmentsofGal-3,wecouldnotdeterminewhetheritscorrelationwith\n[3] Krz\u00e9slakA,LipinskaA.Galectin-3asamultifunctionalprotein.CellMolBiolLett\nrenal function wasconstantover time or whether it changedwith 2004;9(2):305\u201328.\nchangesineGFR.ThestudypopulationwaspartofageneralHFpopula- [4] SharmaUC,PokgarelS,vanBrakelTJ,vanBerloJH,CleutjensJP,SchroenB,etal.\ntiontreatedataspecific,multidisciplinaryHFunitinatertiarycarehos- Galectin-3marksactivatedmacrophagesinfailure-pronehypertrophiedhearts\nandcontributestocardiacdysfunction.Circulation2004;110(19):3121\u20138.\npital.MostpatientswererelativelyyoungmenwithHFofischemic [5] LokDJ,VanDerMeerP,delaPortePW,LipsicE,VanWijngaardenJ,HillegeHL,etal.\netiologyandreducedLVEF.Consequently,theseresultsmaynotneces- Prognosticvalueofgalectin-3,anovelmarkeroffibrosis,inpatientswithchronic\nsarilybeextrapolatedtoaglobalHFpopulation.\nheartfailure:datafromtheDEAL-HFstudy.ClinResCardiol2010;99(5):323\u20138.\n[6] VanKimmenadeRR,JanuzziJrJL,EllinorPT,SharmaUC,BakkerJA,LowAF,etal.\nUtilityofamino-terminalpro-brainnatriureticpeptide,galectin-3,andapelinfor\n5.Conclusions theevaluationofpatientswithacuteheartfailure.JAmCollCardiol2006;48(6):\n1217\u201324.\n[7] TangW,ShresthaK,ShaoZ,BorowskiAG,TroughtonRW,ThomasJD,etal.Usefulnessof\nCirculatingGal-3washighlycorrelatedwithrenalfunctioninoutpa- plasmaGalectin-3levelsinsystolicheartfailuretopredictrenalinsufficiencyand\ntientswithHF.ThismightbeinterpretedasevidencethatGal-3isa survival.AmJCardiol2011;108(3):385\u201390.\nrenalmarker,whichreflectsrenalfibrosis.However,otherunknown [8] FelkerGM,FiuzatM,ShawLK,ClareR,WhellanDJ,BettariL,etal.Galectin-3inam-\nbulatorypatientswithheartfailure:resultsfromtheHF-ACTIONstudy.CircHeart\nfactorsmayexplaintheincreasesinGal-3withdecreasesinrenalfunc- Fail2012;5(1):72\u20138.\ntion.ThevalueofGal-3asapredictorofHFprognosisdeclinedafter [9] DeBoerRA,LokDJ,JaarsmaT,vanderMeerP,VoorsAA,HillegeHL,etal.Predictive\nadjustingforrenalfunction;butitsprognosticvaluevariedsignificantly valueofplasmagalectin-3levelsinheartfailurewithreducedandpreservedejection\nfraction.AnnMed2011;43(1):60\u20138.\namonggroupswithdifferenteGFRs. [10] Lopez-Andr\u00e9sN,RossignolP,IraqiW,FayR,Nu\u00e9eJ,GhioS,etal.Associationof\nSupplementarydatatothisarticlecanbefoundonlineathttp://dx. galectin-3andfibrosismarkerswithlong-termcardiovascularoutcomesinpatients\ndoi.org/10.1016/j.ijcard.2014.09.011. withheartfailure,leftventriculardysfunction,anddyssynchrony:insightsfromthe\nCARE-HF(CardiacResynchronizationinHeartFailure)trial.EurJHeartFail2012;\n14(1):74\u201381.\nConflictofinterest [11] AnandIS,RecotTS,KuskowskiM,AdourianA,MuntendamP,CohnJN.Baselineand\nserialmeasurementsofgalectin-3inpatientswithheartfailure:relationshipto\nprognosisandeffectoftreatmentwithvalsartanintheVal-HeFT.EurJHeartFail\nTheauthor/sreport/snorelationshipsthatcouldbeconstruedasa 2013;15(5):511\u20138.\nconflictofinterest. [12] LainscakM,ColettaAP,SherwiN,ClelandJG.ClinicaltrialsupdatefromtheHeart\nFailureSocietyofAmericaMeeting2009:FAST,IMPROVE-HF,COACHGalectin-3\nsubstudy,HF-ACTIONNuclearsubstudy,DAD-HF,andMARVEL-1.EurJHeartFail\nAcknowledgments 2010;12(2):193\u20136.\n[13] Bayes-GenisA,deAntonioM,VilaJ,Pe\u00f1afielJ,Gal\u00e1nA,BarallatJ,etal.Head-to-head\ncomparisonof2fibrosisbiomarkersforlong-termheartfailureriskstratification.ST-\nWe thank Beatriz Gonz\u00e1lez, Roser Cabanes, and Margarita 2versusGalectin-3.JAmCollCardiol2014;63(2):158\u201366.\nRodr\u00edguez,nursesintheHFUnit,forthedatacollectionandinvaluable [14] Lup\u00f3nJ,deAntonioM,Gal\u00e1nA,VilaJ,ZamoraE,UrrutiaA,etal.Combineduseofthe\nworkintheunit.WealsowishtoacknowledgeRedesTem\u00e1ticasde\nnovelbiomarkershigh-sensitivitytroponinTandST2forheartfailureriskstratifica-\ntionvsconventionalassessment.MayoClinProc2013;88(3):234\u201343.\nInvestigaci\u00f3n Cooperativa en Salud (RETICS), Red Cardiovascular [15] Bayes-GenisA,deAntonioM,Gal\u00e1nA,SanzH,UrrutiaA,CabanesR,etal.Combined\n(RD12/0042/0047). useofhigh-sensitivityST2andNTproBNPtoimprovethepredictionofdeathin\nheartfailure.EurJHeartFail2012;14(1):32\u20138.\n[16] LeveyAS,StevensLA,SchmidCH,ZhangYL,Castro3rdAF,FeldmanHI,etal.CKD-EPI\nReferences (ChronicKidneyDiseaseEpidemiologyCollaboration).Anewequationtoestimate\nglomerularfiltrationrate.AnnInternMed2009;150(9):604\u201312[Erratumin:Ann\n[1] McMurrayJJ,AdamopoulosS,AnkerSD,AuricchioA,B\u00f6hm,DicksteinK,etal.ESC InternMed.2011;155(6):408].\nCommitteeforPracticeGuidelines.ESCGuidelinesforthediagnosisandtreatment [17] InkerLA,SchmidCH,TighiouartH,EckfeldtJH,FeldmanHI,GreeneT,etal.Estimating\nofacuteandchronicheartfailure2012:theTaskForcefortheDiagnosisandTreat- glomerularfiltrationratefromserumcreatinineandcystatinC.NEnglJMedJul5\nmentofAcuteandChronicHeartFailure2012oftheEuropeanSocietyofCardiology. 2012;367(1):20\u20139.\nEurHeartJ2012;33(14):1787\u2013847. [18] Bayes-GenisA,ZamoraE,deAntonioM,Gal\u00e1nA,VilaJ,UrrutiaA,etal.SolubleST2\n[2] JessupM,AbrahamWT,CaseyDE,FeldmanAM,FrancisGS,GaniatsTG,etal.2009 serumconcentrationandrenalfunctioninheartfailure.JCardFail2013;19(11):\nfocusedupdate:ACCF/AHAGuidelinesfortheDiagnosisandManagementofHeart 768\u201375.\nFailureinAdults:areportoftheAmericanCollegeofCardiologyFoundation/ [19] MannDL.Mechanismsandmodelsinheartfailure.Acombinatorialapproach.Circu-\nAmerican Heart Association Task Force on Practice Guidelines: developed in lation1999;100(9):999\u20131008.\nE.Zamoraetal./InternationalJournalofCardiology177(2014)171\u2013177 177\n[20] HendersonNC,MackinnonAC,FarnworthSL,KipariT,HaslettC,IredaleJP,etal. [27] OkamuraDM,PasichnykK,Lopez-GuisaJM,CollinsS,HsuDK,LiuFT,etal.Galectin-3\nGalectin-3expressionandsecretionlinksmacrophagestothepromotionofrenal preservesrenaltubulesandmodulatesextracellularmatrixremodelinginprogres-\nfibrosis.AmJPathol2008;172(2):288\u201398. sivefibrosis.AmJPhysiolRenalPhysiol2010;300(1):F245\u201353.\n[21]GopalDM,KommineniM,AyalonN,KoelblC,AyalonR,BioloA,etal.Relationshipof [28] LassusJ,HarjolaV,SundR,Siiril\u00e4-WarisK,MelinJ,PeuhkurinenK,etal.Prognostic\nplasmagalectin-3torenalfunctioninpatientswithheartfailure:effectsofclinical valueofCystatin-Cinacuteheartfailureinrelationtoothermarkersofrenalfunc-\nstatus,pathophysiologyofheartfailure,andpresenceorabsenceofheartfailure.J tionandNT-proBNP.EurHeartJ2007;28(15):1841\u20137.\nAmHeartAssocOct2012;1(5):e000760. [29] IxJH,ShlipackMG,ChertowGM,AliS,SchillerNB,WhooleyMA,etal.Cystatin-C,left\n[22]ShahRV,Chen-TournouxAA,PicardMH,vanKimmenadeRR,JanuzziJL.Galectin-3, ventricularhypertrophy,anddiastolicdysfunction:datafromtheHeartandSoul\ncardiacstructureandfunction,andlong-termmortalityinpatientswithacutelyde- Study.JCardFail2006;12(8):601\u20137.\ncompensatedheartfailure.EurJHeartFail2010;12(8):826\u201332. [30] ZamoraE,Lup\u00f3nJ,deAntonioM,VilaJ,Gal\u00e1nA,GastelurrutiaP,etal.Limitedvalue\n[23] Beiras-FernandezA,WeisF,RothkopfJ,KaczmarekI,LedderoseC,DickA,etal. ofcystatin-Coverestimatedglomerularfiltrationrateforheartfailureriskstratifica-\nLocalexpressionofmyocardialgalectin-3doesnotcorrelatewithitsserum tion.PLoSOne2012;7(12):e51234.\nlevelsinpatientsundergoinghearttransplantation.AnnTransplant2013;18: [31] ZamoraE,LuponJ,deAntonioM,VilaJ,Pe\u00f1afielJ,Gal\u00e1nA,etal.Long-termprognos-\n643\u201350. ticvalueforpatientswithchronicheartfailureofestimatedglomerularfiltration\n[24]NativiJJ,KremersWK,HasinT,AbouEzzeddineO,KushwahaSS,EdwardsBS,etal. ratecalculatedwiththeNewCKD-EPIequationscontainingcystatin-C.ClinChem\nGalectin-3,abiomarkerofpoorprognosisinheartfailureremainsunchangedafter 2014;60(3):481\u20139.\nhearttransplantation.Paperpresentedat:AHACongress;November4\u20136,2012; [32] HoJE,LiuC,LyassA,CourchesneP,PencinaMJ,VasanRS,etal.Higherconcentration\nLosAngeles,CA;2012. ofGal-3,amarkerofcardiacfibrosis,isassociatedwithincreasedriskforincidentHF\n[25] DangZ,MacKinnonA,MarsonLP,SethiT.Tubularatrophyandinterstitialfibrosis andmortality.Galectin-3,amarkerofcardiacfibrosis,predictsincidentheartfailure\nafterrenaltransplantationisdependentongalectin-3.Transplantation2012; inthecommunity.JAmCollCardiol2012;60(14):1249\u201356.\n93(5):477\u201384. [33] O'SeaghdhaCM,HwangSJ,HoJE,VasanRS,LevyD,FoxCS,etal.Elevatedgalectin-3\n[26] FernandesBertocchiAP,CampanholeG,WangPH,Gon\u00e7alvesGM,Dami\u00e3oMJ, precedesthedevelopmentofCKD.JAmSocNephrol2013;24(9):1470\u20137.\nCenedezeMA,etal.ARoleforgalectin-3inrenaltissuedamagetriggeredby\nischemiaandreperfusioninjury.TransplInt2008;21(10):999\u20131007.",
  "source": "sci-hub",
  "retrieved_at": "2025-01-05T18:51:12Z"
}